Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum–Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

Goshi Nishimura,Hiromitsu Hatakeyama,Osamu Shiono,Masataka Taguri,Masanori Komatsu,Daisuke Sano,Naoko Sakuma,Kenichiro Yabuki,Yasuhiro Arai,Kunihiko Shibata,Yoshihiro Chiba,Teruhiko Tanabe,Nobuhiko Oridate

Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum–Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

2018

Goshi Nishimura
Hiromitsu Hatakeyama
Osamu Shiono
Masataka Taguri
Masanori Komatsu
Daisuke Sano
Naoko Sakuma
Kenichiro Yabuki
Yasuhiro Arai
Kunihiko Shibata
Yoshihiro Chiba
Teruhiko Tanabe
Nobuhiko Oridate

Background We confirmed the safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel in a small number of patients with cis-platinum–intolerant core high-risk head and neck cancer.

Keywords:

Clinical trial
Physical therapy
Cetuximab
Oncology
Medicine
Chemoradiotherapy
Cis-platinum
Head and neck cancer
Docetaxel
Internal medicine
Radiation therapy
Clinical endpoint
Radiology
Survival rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations